Sol-Gel Technologies Target Price Surges to $50 Following Analyst Upgrade
Sol-Gel Technologies (NASDAQ:SLGL) has seen its price target significantly increased from $6.00 to $50.00 by HC Wainwright, according to a research note released on Monday. The investment firm has maintained a buy rating on the stock, suggesting strong confidence in the company’s future performance.
In their projections, HC Wainwright estimated earnings per share (EPS) for the upcoming quarters. They predict a loss of ($2.09) EPS for Q3 2025, turning to a profit of $0.40 EPS in Q4 2025. For the full fiscal year 2025, the firm expects ($0.68) EPS, with further anticipated losses into 2026, including ($1.63) EPS in Q1 2026 and ($1.74) EPS in Q2 2026.
Several other brokerages have shared their views on Sol-Gel Technologies. On October 8, 2023, Weiss Ratings reaffirmed a “hold (c-)” rating for the company’s shares. Earlier, on September 13, 2023, Wall Street Zen upgraded the stock to a “buy” rating. Currently, one analyst has rated the stock as a Buy, while another has assigned it a Hold rating. As reported by MarketBeat.com, Sol-Gel Technologies enjoys a consensus rating of “Moderate Buy” with an average target price of $50.00.
Recent Earnings Report Shows Positive Surprises
Sol-Gel Technologies reported its quarterly earnings on August 15, 2023, delivering an EPS of $4.17, significantly exceeding the consensus estimate of ($0.67) by $4.84. The company’s performance was bolstered by revenue of $17.26 million, surpassing analyst estimates of $2.86 million. Despite this positive news, Sol-Gel Technologies recorded a negative return on equity of 11.80% and a net margin of 14.25%.
Looking ahead, analysts forecast that the company will post an EPS of ($0.28) for the current fiscal year.
About Sol-Gel Technologies
Based in Israel, Sol-Gel Technologies Ltd., along with its subsidiary Sol-Gel Technologies Inc., specializes in developing topical dermatological treatments for patients with serious skin conditions. Among its key products are Twyneo, a once-daily, non-antibiotic topical cream designed for the treatment of acne vulgaris, and Epsolay, a daily topical cream aimed at addressing papulopustular (subtype II) rosacea.
The recent upgrade in Sol-Gel Technologies’ target price reflects growing confidence in its product lines and market strategy, positioning the company as a potential leader in dermatological treatments.
